MRZ-99030 is an Aβ aggregation modulator. MRZ-99030 triggers a non-amyloidogenic aggregation pathway, thereby reducing the amount of intermediate toxic soluble oligomeric Aβ species.
PD 142505-0028, a functionally M1-selective muscarinic agonist, rapidly increases glutamate but not aspartate concentrations in the striatum of anesthetized rats. Additionally, it inhibited production of amyloidogenic A beta and increased secretion of sol
Pramlintide is a non-amyloidogenic analog of the antidiabetic peptide hormone amylin that contains proline residues substituted at positions 25, 28, and 29. It stimulates cAMP production in HEK293 cells expressing human amylin receptor 1a (AMY1a), AMY2a, and AMY3a (EC50s = 0.35, 22.9, and 0.89 nM, respectively). Pramlintide inhibits human islet amyloid polypeptide fibrilization in a concentration-dependent manner. In vivo, pramlintide (200 pg/kg) reduces brain levels of amyloid-β (1-40) and increases spontaneous alternation in the Y-maze in the Tg2576 transgenic mouse model of Alzheimer's disease.
Eprodisate is a novel compound specifically developed to disrupt the interactions between amyloidogenic proteins and glycosaminoglycans, effectively impeding the polymerization of amyloid fibrils and their deposition in tissues. This compound shows potential for delaying the advancement of AA amyloidosis-related renal disease and could apply to various forms of amyloidosis.
β-Amyloid (1-16) is an amyloidogenic protein fragment with a sequence derived from β-amyloid. It exhibits the ability to bind to metal ions, indicating its involvement in metal-binding processes. β-Amyloid, a peptide, is responsible for the formation of amyloid plaques in the brains of individuals affected by Alzheimer's disease (AD).